Discovery of highly selective and potent p38 inhibitors based on a phthalazine scaffold

Journal of Medicinal Chemistry

Volumn 51, Issue 20, 2008, Pages 6271-6279

  Herberich, Brad ^a   Cao, Guo Qiang ^a   Chakrabarti, Partha P ^a   Falsey, James R ^a   Pettus, Liping ^a   Rzasa, Robert M ^a   Reed, Anthony B ^a   Reichelt, Andreas ^a   Sham, Kelvin ^a   Thaman, Maya ^a   Wurz, Ryan P ^a   Xu, Shimin ^a   Zhang, Dawei ^a   Hsieh, Faye ^a   Lee, Matthew R ^a   Syed, Rashid ^a   Li, Vivian ^a   Grosfeld, David ^a   Plant, Matthew H ^a   Henkle, Bradley ^a   Sherman, Lisa ^a   Middleton, Scot ^a   Lu, Min Wong ^a   Tasker, Andrew S ^a   more..

^a AMGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DEXAMETHASONE; INTERLEUKIN 8; LIPOPOLYSACCHARIDE; MITOGEN ACTIVATED PROTEIN KINASE P38; MITOGEN ACTIVATED PROTEIN KINASE P38 INHIBITOR; N CYCLOPROPYL 4 METHYL 3 [1 (2,2,2 TRIFLUORO 1 METHYLETHOXY) 6 PHTHALAZINYL]BENZAMIDE; PHTHALAZINE DERIVATIVE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADJUVANT ARTHRITIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IC 50; MALE; NONHUMAN; RAT; STRUCTURE ACTIVITY RELATION;

ANIMALS; CELLS, CULTURED; CRYSTALLOGRAPHY, X-RAY; DRUG EVALUATION, PRECLINICAL; HUMANS; MITOGEN-ACTIVATED PROTEIN KINASE 14; MODELS, MOLECULAR; MOLECULAR STRUCTURE; PHTHALAZINES; PROTEIN KINASE INHIBITORS; QUINOLINES; RATS; SENSITIVITY AND SPECIFICITY; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 54549083435     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm8005417     Document Type: Article

References (28)

1. (a) Saxne, T.; Palladino, M. J.; Heinegard, D.; Talal, N.; Wollheim, F. Detection of Tumor Necrosis Factor α but Not Tumor Necrosis Factor β in Rheumatoid Arthritis Synovial Fluid and Serum. Arthritis Rheum. 1988, 31, 1041-1045.
2. (b) Arend, W.; Dayer, J. Cytokines and Cytokine Inhibitors or Antagonists in Rheumatoid Arthritis. Arthritis Rheum. 1990, 33, 305-315.
3. For a recent review, see the following, (c) Tracey, D.; Klareskog, L.; Sasso, E. H.; Salfeld, J. G.; Tak, P. P. Pharmacol. Ther. 2008, 117, 244-279.
4. (a) Jarvis, B.; Faulds, D. Etanercept: A Review of Its Use in Rheumatoid Arthritis. Drugs 1999, 57, 945-966.
5. (b) Garrison, L.; McDonnell, N. D. Etanercept: Therapeutic Use in Patients with Rheumatoid Arthritis. Ann. Rheum. Dis 1999, 58 (Suppl. 1), 65-69.
6. (c) Mease, P. J.; Goffe, B. S.; Metz, J.; VanderStoep, A.; Finck, B.; Burge, D. J. Etanercept in the Treatment of Psoriatic Arthritis and Psoriasis: A Randomized Trial. Lancet 2000, 356, 385-390.
7. (d) Carteron, N. L. Cytokines in Rheumatoid Arthritis: Trial and Tribulations. Mol. Med. Today 2000, 6, 315-323.
8. (e) Maini, R.; St. Clair, E. W.; Breedveld, F.; Furst, F.; Kalden, J.; Weisman, M.; Smolen, J.; Emery, P.; Harriman, G.; Feldmann, M.; Lipsky, P. Infliximab (Chimeric Anti-Tumor Necrosis Factor Alpha Monoclonal Antibody) versus Placebo in Rheumatoid Arthritis Patients Receiving Concomitant Methotrexate: A Randomized Phase III Trial. Lancet 1999, 354, 1932-1939.
9. (f) Present, D. H.; Rutgeerts, P.; Targan, S.; Hanauer, S. B.; Mayer, L.; van Hogezand, R. A.; Podolsky, D. K.; Sands, B. E.; Braakman, T.; DeWoody, K. L.; Schaible, T. F.; van Deventer, S. J. Infliximab for the Treatment of Fistulas in Patients with Crohn'S Disease. N. Engl. J. Med. 1999, 340, 1398-1405.
10. (g) Bang, L. M.; Keating, G. M. Adalimumab, a Review of Its Use in Rheumatoid Arthritis. BioDrugs 2004, 18, 121-139.
11. (a) Palladino, M. A.; Bahjat, F. R.; Theodorakis, E. A.; Moldawer, L. L. Anti-TNF-α Therapies: The Next Generation. Nat. Rev. Drug Discovery 2003, 2, 736-746.
12. (b) Bongartz, T.; Sutton, A. J.; Sweeting, M. J.; Buchan, I.; Matteson, E. L.; Montori, V. Anti-TNF Antibody Therapy in Rheumatoid Arthritis and the Risk of Serious Infections and Malignacies Systematic Review and Meta-analysis of Rare Harmful Effects in Randomized Controlled Trials. JAMA, J. Am. Med. Assoc. 2006, 295, 2275-2285.
13. (a) Laydon, J. T.; McDonnell, P. C.; Gallagher, T. F.; Kumar, S.; Green, D.; McNulty, D.; Blumenthal, M. J.; Heyes, J. R. A Protein Kinase Involved in the Regulation of Inflammatory Cytokine Biosynthesis. Nature 1994, 372, 739-746.
14. (b) Saklatvala, J. The p38 MAP Kinase Pathway as a Therapeutic Target in Inflammatory Disease. Curr. Opin. Pharmacol. 2004, 4, 372-377.
15. (c) Kumar, S.; Boehm, J.; Lee, J. C. p38 MAP Kinases: Key Signalling Molecules as Therapeutic targets for Inflammatory Diseases. Nat. Rev. Drug Discovery 2003, 2, 717-726.
16. O'Keefe, S. J.; Mudgett, J. S.; Cupo, S.; Parsons, J. N.; Chartrain, N. A.; Fitzgerald, C.; Chen, S.-L.; Lowitz, K.; Rasa, C.; Visco, D.; Luell, S.; Carballo-Jane, E.; Owens, K.; Zaller, D. M. Chemical Genetics Define the Roles of p38α and p38β in Acute and Chronic Inflammation. J. Biol. Chem. 2007, 282, 34663-34671.
17. (a) Peifer, C.; Wagner, G.; Laufer, S. New Approaches to the Treatment of Inflammatory Disorders Small Molecule Inhibitors of p38 MAP Kinase. Curr. Top. Med. Chem. 2006, 6, 113-149.
18. (b) Hynes, J., Jr.; Leftheris, K. Small Molecule p38 Inhibitors: Novel Structural Features and Advances from 2002-2005. Curr. Top. Med. Chem. 2005, 5, 967-985.
19. (c) Dominguez, C.; Tamayo, C.; Zhang, D. p38 Inhibitors: Beyond Pyridinylimidazoles. Expert Opin. Ther. Pat. 2005, 15, 801-816.
20. (d) Goldstein, D. M.; Gabriel, T. Pathway to the Clinic: Inhibition of p38 MAP Kinase. A Review of Ten Chemotypes Selected for Development. Curr. Top. Med. Chem. 2005, 5, 1017-1029.
21. (a) Fitzgerald, C. E.; Patel, S. B.; Becker, J. W.; Cameron, P. M.; Zaller, D.; Pikounis, V. B.; O'Keefe, S. J.; Scapin, G. Structural Basis for p38α MAP Kinase Quinazolinone and Pyridol-Pyrimidine Inhibitor Specificity. Nat. Struct. Biol. 2003, 10, 764-769.
22. (b) Stelmach, J. E.; Liu, L.; Sangita, P. B.; Pivnichny, J. V.; Scapin, G.; Singh, S.; Hop, C. E. C. A.; Wang, Z.; Strauss, J. R.; Cameron, P. M.; Michols, E. A.; O'Keefe, S. J.; O'Neill, E. A.; Schmatz, D. M.; Schwartz, C. D.; Thompson, C. M.; Zaller, D. M.; Doherty, J. B. Design and Synthesis of Potent, Orally Bioavailable Dihydroquinazolinone Inhibitors of p38 MAP Kinase. Bioorg. Med. Chem. Lett. 2003, 13, 277-280.
23. (c) Angell, R. M.; Bamborough, P; Cleasby, A.; Cockerill, S. G.; Jones, K. L.; Mooney, C. J.; Somers, D, O.; Walker, A. L. Biphenyl Amide p38 Kinase Inhibitors 1: Discover and Binding Mode. Bioorg. Med. Chem. Lett. 2008, 18, 318-323.
24. (a) Bakthavatchatam, R.; Blum, C. A.; Brielmann, H. L.; Caldwell, T. M.; De Lombaert, S. Substituted Quinazolin-4-ylamine Analogues. WO 030662209 A2, 2003.
25. For an alternative synthesis, see the following: (b) Zhang, X.; Nirschl, A. A.; Zou, Y.; Priestly, E. S. Phenylglycinamide and Pyridylglycinamide Derivatives Useful as Anticoagulants. WO 07002313 A2, 2007.
26. Angell, R. M.; Baldwin, I. R.; Bamborough, P.; Deboeck, N. M.; Longstaff, T.; Swanson, S. Preparation of Fused Heteroaryls, in Particular Benzisoxazoles and Indazoles for Use as p38 Inhibitors in the Treatment of Rheumatoid Arthritis. WO 04010995 A1, 2004.
27. Barber, C. G.; Fish, P. V.; Dickinson, R. P. Isoquinoline as Urokinase Inhibitors. WO 9920608 A1, 1999.
28. DiMauro, E. F.; Newcomb, J.; Nunes, J. J.; Bemis, J. E.; Boucher, C.; Buchanan, J. L.; Buckner, W. H.; Cee, V. J.; Chai, L.; Deak, H. L.; Epstein, L. F.; Faust, T.; Gallant, P.; Geuns-Meyer, S. D.; Gore, A.; Gu, Y.; Henkle, B.; Hodous, B. L.; Hsieh, F.; Huang, X.; Kim, J. L.; Lee, J. H.; Martin, M. W.; Masse, C. E.; McGowan, D. C.; Metz, D.; Mohn, D.; Morgenstern, K. A.; Oliveria-dos-Santos, A.; Patel, V. F.; Powers, D.; Rose, P. E.; Schneider, S.; Tomlinson, S. A.; Tudor, Y.-Y.; Turci, S. M.; Welcher, A. A.; White, R. D.; Zhao, H.; Zhu, L.; Zhu, X. Discovery of Aminoquinazolines as Potent, Orally Bioavailable Inhibitors of Lck: Synthesis, SAR and in Vivo Anti-Inflammatory Activity. J. Med Chem. 2006, 49, 5671-5686.